• Blueprint Medicines EPS for the quarter ending December 31, 2024 was $-0.78, a 57.38% decline year-over-year.
• Blueprint Medicines 2024 annual EPS was $-1.07, a 87.22% decline from 2023.
• Blueprint Medicines 2023 annual EPS was $-8.37, a 10.48% decline from 2022.
• Blueprint Medicines 2022 annual EPS was $-9.35, a 15.08% decline from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.